Robert E Hollingsworth
Overview
Explore the profile of Robert E Hollingsworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho H, Binder J, Weeratna R, Dermyer M, Dai S, Boccia A, et al.
Cancer Immunol Immunother
. 2022 Jul;
72(2):287-300.
PMID: 35829790
The development of therapeutic cancer vaccines remains an active area, although previous approaches have yielded disappointing results. We have built on lessons from previous cancer vaccine approaches and immune checkpoint...
2.
Hollingsworth R, Jansen K
NPJ Vaccines
. 2019 Feb;
4:7.
PMID: 30774998
Recent advances in several areas are rekindling interest and enabling progress in the development of therapeutic cancer vaccines. These advances have been made in target selection, vaccine technology, and methods...
3.
Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al.
Mol Cancer Ther
. 2017 May;
16(8):1576-1587.
PMID: 28522587
Antibody-drug conjugates (ADC) are used to selectively deliver cytotoxic agents to tumors and have the potential for increased clinical benefit to cancer patients. 5T4 is an oncofetal antigen overexpressed on...
4.
Kerk S, Finkel K, Pearson A, Warner K, Zhang Z, Nor F, et al.
Clin Cancer Res
. 2016 Nov;
23(10):2516-2527.
PMID: 27780858
Locoregional recurrence is a frequent treatment outcome for patients with advanced head and neck squamous cell carcinoma (HNSCC). Emerging evidence suggests that tumor recurrence is mediated by a small subpopulation...
5.
Hay C, Sult E, Huang Q, Mulgrew K, Fuhrmann S, McGlinchey K, et al.
Oncoimmunology
. 2016 Sep;
5(8):e1208875.
PMID: 27622077
MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of...
6.
Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, et al.
J Control Release
. 2016 Jun;
236:100-16.
PMID: 27327768
Antibody-drug conjugates (ADCs) are among the most promising empowered biologics for cancer treatment. ADCs are commonly prepared by chemical conjugation of small molecule cytotoxic anti-cancer drugs to antibodies through either...
7.
Hu Y, Lu L, Xia Y, Chen X, Chang A, Hollingsworth R, et al.
Cancer Res
. 2016 Jun;
76(16):4661-72.
PMID: 27325649
Dendritic cell (DC)-based vaccine strategies aimed at targeting cancer stem-like cells (CSC) may be most efficacious if deployed in the adjuvant setting. In this study, we offer preclinical evidence that...
8.
Finkel K, Warner K, Kerk S, Bradford C, McLean S, Prince M, et al.
Neoplasia
. 2016 May;
18(5):273-281.
PMID: 27237319
Head and neck squamous cell carcinomas (HNSCC) exhibit a small population of uniquely tumorigenic cancer stem cells (CSC) endowed with self-renewal and multipotency. We have recently shown that IL-6 enhances...
9.
Xiao Z, Carrasco R, Schifferli K, Kinneer K, Tammali R, Chen H, et al.
Mol Cancer Ther
. 2016 Feb;
15(4):689-701.
PMID: 26880266
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and activated in human cancers. HER3 is a compelling cancer target due to...
10.
Zhong H, Davis A, Ouzounova M, Carrasco R, Chen C, Breen S, et al.
Cancer Res
. 2016 Jan;
76(2):480-90.
PMID: 26744529
Elevated levels of the proinflammatory cytokine IL6 are associated with poor survival outcomes in many cancers. Antibodies targeting IL6 and its receptor have been developed for chronic inflammatory disease, but...